BIOMERICA INC (BMRA)

US09061H3075 - Common Stock

0.2789  +0.01 (+4.85%)

Fundamental Rating

2

Taking everything into account, BMRA scores 2 out of 10 in our fundamental rating. BMRA was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While BMRA seems to be doing ok healthwise, there are quite some concerns on its profitability. BMRA does not seem to be growing, but still is valued expensively.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BMRA has reported negative net income.
In the past year BMRA has reported a negative cash flow from operations.
BMRA had negative earnings in each of the past 5 years.
In the past 5 years BMRA always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -78.30%, BMRA is doing worse than 78.07% of the companies in the same industry.
With a Return On Equity value of -115.26%, BMRA is not doing good in the industry: 66.84% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -78.3%
ROE -115.26%
ROIC N/A
ROA(3y)-51.28%
ROA(5y)-46.48%
ROE(3y)-68.67%
ROE(5y)-61.12%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

BMRA has a worse Gross Margin (8.81%) than 81.82% of its industry peers.
In the last couple of years the Gross Margin of BMRA has declined.
BMRA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 8.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.97%
GM growth 5Y-14.58%

More info and screens

6

2. Health

2.1 Basic Checks

BMRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BMRA remains at a similar level compared to 1 year ago.
BMRA has more shares outstanding than it did 5 years ago.
There is no outstanding debt for BMRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -9.07, we must say that BMRA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -9.07, BMRA is not doing good in the industry: 80.21% of the companies in the same industry are doing better.
There is no outstanding debt for BMRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.07
ROIC/WACCN/A
WACC9.16%

2.3 Liquidity

BMRA has a Current Ratio of 3.00. This indicates that BMRA is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.00, BMRA perfoms like the industry average, outperforming 54.55% of the companies in the same industry.
BMRA has a Quick Ratio of 2.09. This indicates that BMRA is financially healthy and has no problem in meeting its short term obligations.
BMRA's Quick ratio of 2.09 is in line compared to the rest of the industry. BMRA outperforms 50.80% of its industry peers.
Industry RankSector Rank
Current Ratio 3
Quick Ratio 2.09

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.78% over the past year.
Looking at the last year, BMRA shows a small growth in Revenue. The Revenue has grown by 1.79% in the last year.
Measured over the past years, BMRA shows a small growth in Revenue. The Revenue has been growing by 0.81% on average per year.
EPS 1Y (TTM)12.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.76%
Revenue 1Y (TTM)1.79%
Revenue growth 3Y-9.06%
Revenue growth 5Y0.81%
Sales Q2Q%5.67%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BMRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BMRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOMERICA INC

NASDAQ:BMRA (12/20/2024, 8:00:01 PM)

0.2789

+0.01 (+4.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-22 2024-10-22/amc
Earnings (Next)01-14 2025-01-14
Inst Owners17.12%
Inst Owner Change-21.87%
Ins Owners7.22%
Ins Owner Change25.81%
Market Cap4.69M
Analysts85.71
Price Target13.26 (4654.39%)
Short Float %9.13%
Short Ratio1.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.85
P/FCF N/A
P/OCF N/A
P/B 0.88
P/tB 0.91
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS0.33
BVpS0.32
TBVpS0.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -78.3%
ROE -115.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 8.81%
FCFM N/A
ROA(3y)-51.28%
ROA(5y)-46.48%
ROE(3y)-68.67%
ROE(5y)-61.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.97%
GM growth 5Y-14.58%
F-Score3
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 67.07%
Cap/Sales 1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3
Quick Ratio 2.09
Altman-Z -9.07
F-Score3
WACC9.16%
ROIC/WACCN/A
Cap/Depr(3y)97.33%
Cap/Depr(5y)119.71%
Cap/Sales(3y)1.51%
Cap/Sales(5y)2.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.76%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.79%
Revenue growth 3Y-9.06%
Revenue growth 5Y0.81%
Sales Q2Q%5.67%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-126.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-136.38%
OCF growth 3YN/A
OCF growth 5YN/A